Pfizer reports phase 3 clinical trial results for Lyme disease vaccine candidate
Pfizer announced results from a phase 3 clinical trial of its Lyme disease vaccine candidate, showing more than 70 percent effectiveness at preventing the illness. The vaccine was developed in partnership with Valneva. This represents a significant development in Lyme disease prevention, as there is currently no approved vaccine for the disease in the United States.
8
Divergence score
2 outlets covered it, splitting into 2 framing camps across 2 bias groups.
2 camps
2 bias groups
The spectrum · how 2 outlets placed this story
LeftCenterRight
The Hill
Wall Street Journal
Supportive of action
Neutral
Dismissive
Critical
Alarmist
International angle
How each outlet covered it
Lightly covered so far
Too few outlets to map a left-right split. Here is each take as it stands.
Sparse coverage · 2 outlets
“Pfizer's Lyme disease vaccine candidate shows promising results”
“Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial - WSJ”
Tracked claims from across the political spectrum
Fact ledger
Corroborated
Disputed